Fate Therapeutics Inc.

NASDAQ: FATE · Real-Time Price · USD
1.09
0.02 (1.87%)
At close: Aug 15, 2025, 3:59 PM
1.09
-0.46%
After-hours: Aug 15, 2025, 04:10 PM EDT

Fate Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
13.63M 63.53M 96.3M 55.85M
Cost of Revenue
18.96M 18.28M 13.76M 5.85M
Gross Profit
13.63M -93.65M 82.54M 50M
Operating Income
-210.28M -190.51M -308.39M -216.99M
Interest Income
17.29M 17.19M 5.84M 1.31M
Pretax Income
-186.26M -160.93M -281.72M -212.15M
Net Income
-186.26M -160.93M -281.72M -212.15M
Selling & General & Admin
74.17M 81.45M 84.23M 57.32M
Research & Development
135M 172.6M 320.45M 215.52M
Other Expenses
14.74M -157.19M -13.76M -5.85M
Operating Expenses
223.91M 96.86M 390.93M 266.99M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
223.91M 254.04M 404.69M 272.84M
Income Tax Expense
n/a n/a -26.66M -5.85M
Shares Outstanding (Basic)
113.69M 98.41M 96.83M 94.75M
Shares Outstanding (Diluted)
113.69M 98.41M 96.83M 94.75M
EPS (Basic)
-1.64 -1.64 -2.91 -2.24
EPS (Diluted)
-1.64 -1.64 -2.91 -2.24
EBITDA
-176.58M -172.23M -294.63M -211.14M
EBIT
-195.54M -190.51M -308.39M -216.99M
Depreciation & Amortization
18.96M 18.28M 13.76M 5.85M